中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 37 Issue 6
Jun.  2021
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(6): 1435-1439

Role of the JAK/STAT/SOCS signaling pathway in hepatitis B virus-related liver diseases

DOI: 10.3969/j.issn.1001-5256.2021.06.045
  • 1.

    Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China

  • 2.

    School of Public Health, Kunming Medical University, Kunming 650500, China

  • Received Date: 2020-10-29
  • Accepted Date: 2020-11-25
  • Published Date: 2021-06-20
    Abstract
  • The JAK/STAT/SOCS signaling pathway can mediate a variety of cytokines involved in inflammation, tumor, and autoimmune diseases and it also plays an important role in hepatitis B virus (HBV) infection-related liver diseases. This article briefly reviews the structure and signal pathway regulation of JAK-STAT and SOCS and elaborates on their role in the development and progression of HBV-related chronic hepatitis B, liver cirrhosis, liver failure, and hepatocellular carcinoma. The final analysis shows that the JAK/STAT/SOCS signaling pathway is dysregulated in HBV-related liver disease and is involved in the development and progression of the disease, and it may even influence the treatment and prognosis of the disease.

     

    • FullText(HTML)
    • References(48)
  • [1]
    WHO. Global hepatitis report, 2017[EB/OL].[2019-11-06]. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
    [2]
    LIU J, LIANG W, JING W, et al. Countdown to 2030: Eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
    [3]
    SEIF F, KHOSHMIRSAFA M, AAZAMI H, et al. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells[J]. Cell Commun Signal, 2017, 15(1): 23. DOI: 10.1186/s12964-017-0177-y.
    [4]
    BOUSOIK E, MONTAZERI ALIABADI H. "Do We Know Jack" About JAK? A closer look at JAK/STAT signaling pathway[J]. Front Oncol, 2018, 8: 287. DOI: 10.3389/fonc.2018.00287.
    [5]
    NABAVI SM, AHMED T, NAWAZ M, et al. Targeting STATs in neuroinflammation: The road less traveled![J]. Pharmacol Res, 2019, 141: 73-84. DOI: 10.1016/j.phrs.2018.12.004.
    [6]
    LIM CP, CAO X. Structure, function, and regulation of STAT proteins[J]. Mol Biosyst, 2006, 2(11): 536-550. DOI: 10.1039/b606246f.
    [7]
    DURHAM GA, WILLIAMS J, NASIM MT, et al. Targeting SOCS proteins to control JAK-STAT signalling in disease[J]. Trends Pharmacol Sci, 2019, 40(5): 298-308. DOI: 10.1016/j.tips.2019.03.001.
    [8]
    MORRIS R, KERSHAW NJ, BABON JJ. The molecular details of cytokine signaling via the JAK/STAT pathway[J]. Protein Sci, 2018, 27(12): 1984-2009. DOI: 10.1002/pro.3519.
    [9]
    YIN Y, LIU W, DAI Y. SOCS3 and its role in associated diseases[J]. Hum Immunol, 2015, 76(10): 775-780. DOI: 10.1016/j.humimm.2015.09.037.
    [10]
    DEES C, PÖTTER S, ZHANG Y, et al. TGF-β-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis[J]. J Clin Invest, 2020, 130(5): 2347-2363. DOI: 10.1172/JCI122462.
    [11]
    SADLER AJ, WILLIAMS BR. Interferon-inducible antiviral effectors[J]. Nat Rev Immunol, 2008, 8(7): 559-568. DOI: 10.1038/nri2314.
    [12]
    YU Y, WAN P, CAO Y, et al. Hepatitis B virus e antigen activates the suppressor of cytokine signaling 2 to repress interferon action[J]. Sci Rep, 2017, 7(1): 1729. DOI: 10.1038/s41598-017-01773-6.
    [13]
    MITRA B, WANG J, KIM ES, et al. Hepatitis B virus precore protein p22 inhibits alpha interferon signaling by blocking STAT nuclear translocation[J]. J Virol, 2019, 93(13): e00196-19. DOI: 10.1128/JVI.00196-19.
    [14]
    CHANG Z, WANG Y, ZHOU X, et al. STAT3 roles in viral infection: Antiviral or proviral?[J]. Future Virol, 2018, 13(8): 557-574. DOI: 10.2217/fvl-2018-0033.
    [15]
    ZANG M, LI Y, HE H, et al. IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(12): 3759-3770. DOI: 10.1016/j.bbadis.2018.10.004.
    [16]
    ZHAO X, SUN L, MU T, et al. An HBV-encoded miRNA activates innate immunity to restrict HBV replication[J]. J Mol Cell Biol, 2020, 12(4): 263-276. DOI: 10.1093/jmcb/mjz104.
    [17]
    WU S, CHEN X, TANG Y, et al. Delivery of Tapasin-modified CTL epitope peptide via cytoplasmic transduction peptide induces CTLs by JAK/STAT signaling pathway in vivo[J]. Acta Biochim Biophys Sin (Shanghai), 2018, 50(2): 181-190. DOI: 10.1093/abbs/gmx133.
    [18]
    HOAN NX, van TONG H, GIANG DP, et al. SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B[J]. Oncotarget, 2017, 8(10): 17127-17139. DOI: 10.18632/oncotarget.15083.
    [19]
    ZHANG P, LI F, LI N, et al. Genetic variations of SOCS1 are associated with chronic hepatitis B virus infection[J]. Hum Immunol, 2014, 75(8): 709-714. DOI: 10.1016/j.humimm.2014.04.010.
    [20]
    TANG LY, HELLER M, MENG Z, et al. Transforming growth factor-β (TGF-β) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway[J]. J Biol Chem, 2017, 292(10): 4302-4312. DOI: 10.1074/jbc.M116.773085.
    [21]
    GU YJ, SUN WY, ZHANG S, et al. Targeted blockade of JAK/STAT3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells[J]. Int J Mol Med, 2016, 38(3): 903-911. DOI: 10.3892/ijmm.2016.2692.
    [22]
    ZHAO J, QI YF, YU YR. STAT3: A key regulator in liver fibrosis[J]. Ann Hepatol, 2021, 21: 100224. DOI: 10.1016/j.aohep.2020.06.010.
    [23]
    MAIR M, BLAAS L, ÖSTERREICHER CH, et al. JAK-STAT signaling in hepatic fibrosis[J]. Front Biosci (Landmark Ed), 2011, 16: 2794-2811. DOI: 10.2741/3886.
    [24]
    ZHANG W, NIU M, YAN K, et al. Stat3 pathway correlates with the roles of leptin in mouse liver fibrosis and sterol regulatory element binding protein-1c expression of rat hepatic stellate cells[J]. Int J Biochem Cell Biol, 2013, 45(3): 736-744. DOI: 10.1016/j.biocel.2012.12.019.
    [25]
    MARTÍ-RODRIGO A, ALEGRE F, MORAGREGA ÁB, et al. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells[J]. Gut, 2020, 69(5): 920-932. DOI: 10.1136/gutjnl-2019-318372.
    [26]
    CHENG C, HUANG C, MA TT, et al. New surprises of suppressor of cytokine signalling in liver fibrosis[J]. Expert Opin Ther Targets, 2014, 18(4): 415-426. DOI: 10.1517/14728222.2014.885953.
    [27]
    YOSHIDA T, OGATA H, KAMIO M, et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis[J]. J Exp Med, 2004, 199(12): 1701-1707. DOI: 10.1084/jem.20031675.
    [28]
    JAMHIRI I, SHAHIN K, KHODABANDEH Z, et al. Recombinant NS3 protein induced expression of immune modulatory elements in hepatic stellate cells during its fibrotic activity[J]. Viral Immunol, 2018, 31(8): 575-582. DOI: 10.1089/vim.2018.0018.
    [29]
    KIM HY, JHUN JY, CHO ML, et al. Interleukin-6 upregulates Th17 response via mTOR/STAT3 pathway in acute-on-chronic hepatitis B liver failure[J]. J Gastroenterol, 2014, 49(8): 1264-1273. DOI: 10.1007/s00535-013-0891-1.
    [30]
    LI Y, HAN MF, LI WN, et al. SOCS3 expression correlates with severity of inflammation in mouse hepatitis virus strain 3-induced acute liver failure and HBV-ACLF[J]. J Huazhong Univ Sci Technolog Med Sci, 2014, 34(3): 348-353. DOI: 10.1007/s11596-014-1281-5.
    [31]
    LI SS, YANG M, CHEN YP, et al. Dendritic cells with increased expression of suppressor of cytokine signaling 1(SOCS1) gene ameliorate lipopolysaccharide/d-galactosamine-induced acute liver failure[J]. Mol Immunol, 2018, 101: 10-18. DOI: 10.1016/j.molimm.2018.05.016.
    [32]
    ZHANG JJ, FAN YC, ZHAO ZH, et al. Prognoses of patients with acute-on-chronic hepatitis B liver failure are closely associated with altered SOCS1 mRNA expression and cytokine production following glucocorticoid treatment[J]. Cell Mol Immunol, 2014, 11(4): 396-404. DOI: 10.1038/cmi.2014.23.
    [33]
    MA HC, WANG X, WU MN, et al. Interleukin-10 contributes to therapeutic effect of mesenchymal stem cells for acute liver failure via signal transducer and activator of transcription 3 signaling pathway[J]. Chin Med J (Engl), 2016, 129(8): 967-975. DOI: 10.4103/0366-6999.179794.
    [34]
    YIN JP, YUE ZC, ZHUO SY. STAT3: A key molecule in the progression of liver cancer mediated by chronic inflammation[J]. J Clin Hepatol, 2020, 36(4): 948-952. DOI: 10.3969/j.issn.1001-5256.2020.04.054.

    音金萍, 岳紫晨, 卓少元. STAT3: 慢性炎症介导肝癌进程的关键分子[J]. 临床肝胆病杂志, 2020, 36(4): 948-952. DOI: 10.3969/j.issn.1001-5256.2020.04.054.
    [35]
    LI TF, SU CY, HUANG G, et al. IL-6 suppresses CCR7 expression in human monocyte-derived dendritic cells via STAT3 pathway[J]. J Third Mil Med Univ, 2015, 37(8): 751-756.
    [36]
    XIONG S, WANG R, CHEN Q, et al. Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling[J]. Am J Cancer Res, 2018, 8(2): 302-316.
    [37]
    YIN Z, MA T, LIN Y, et al. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma[J]. J Cell Biochem, 2018, 119(11): 9419-9432. DOI: 10.1002/jcb.27259.
    [38]
    WANG B, LIU T, WU JC, et al. STAT3 aggravates TGF-β1-induced hepatic epithelial-to-mesenchymal transition and migration[J]. Biomed Pharmacother, 2018, 98: 214-221. DOI: 10.1016/j.biopha.2017.12.035.
    [39]
    CHEN G, WANG H, XIE S, et al. STAT1 negatively regulates hepatocellular carcinoma cell proliferation[J]. Oncol Rep, 2013, 29(6): 2303-2310. DOI: 10.3892/or.2013.2398.
    [40]
    JIN Y, SUN Z, GENG J, et al. IL-21 reinvigorates exhausted natural killer cells in patients with HBV-associated hepatocellular carcinoma in STAT1-depedent pathway[J]. Int Immunopharmacol, 2019, 70: 1-8. DOI: 10.1016/j.intimp.2019.02.007.
    [41]
    GAO MD, ZHANG YH, ZHAO Y. Role of signal transduction and transcription factors STAT1 and STAT3 in the pathogen-esis of hepatocellular carcinoma and liver failure[J]. J Clin Hepatol, 2018, 34(9): 2017-2020. DOI: 10.3969/j.issn.1001-5256.2018.09.040

    高梦丹, 张永宏, 赵艳. STAT1与STAT3在肝细胞癌及肝衰竭发病机制中的作用[J]. 临床肝胆病杂志, 2018, 34(9): 2017-2020. DOI: 10.3969/j.issn.1001-5256.2018.09.040.
    [42]
    KALTENECKER D, THEMANNS M, MUELLER KM, et al. Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression[J]. Cytokine, 2019, 124: 154569. DOI: 10.1016/j.cyto.2018.10.010.
    [43]
    WANG X, LIAO X, YU T, et al. Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma[J]. Int J Oncol, 2019, 55(4): 805-822. DOI: 10.3892/ijo.2019.4862.
    [44]
    ZHANG X, WANG J, CHENG J, et al. An integrated analysis of SOCS1 down-regulation in HBV infection-related hepatocellular carcinoma[J]. J Viral Hepat, 2014, 21(4): 264-271. DOI: 10.1111/jvh.12137.
    [45]
    KHAN M, GHOSH A, VARIYA B, et al. Hepatocyte growth control by SOCS1 and SOCS3[J]. Cytokine, 2019, 121: 154733. DOI: 10.1016/j.cyto.2019.154733.
    [46]
    YANG Z, ZHU H, ZHANG L, et al. DNA methylation of SOCS1/2/3 predicts hepatocellular carcinoma recurrence after liver transplantation[J]. Mol Biol Rep, 2020, 47(3): 1773-1782. DOI: 10.1007/s11033-020-05271-3.
    [47]
    CUI M, SUN J, HOU J, et al. The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma[J]. Tumour Biol, 2016, 37(10): 13521-13531. DOI: 10.1007/s13277-016-5215-7.
    [48]
    ZHANG M, LIU S, CHUA MS, et al. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway[J]. Cell Death Dis, 2019, 10(8): 612. DOI: 10.1038/s41419-019-1856-y.
    • Relative Articles

  • Relative Articles

    [1]Xing YANG, Shudi LI, Jiangkai LIU, Zhen WANG, Suling LI. Current research status of traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma by regulating the JAK/STAT signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(11): 2718-2729. doi: 10.3969/j.issn.1001-5256.2023.11.030
    [2]Hui LIU, Fengmin LU, Jutao GUO. Mechanism of action, clinical research and development, and application prospect of hepatitis B virus core protein allosteric modulators[J]. Journal of Clinical Hepatology, 2022, 38(8): 1726-1732. doi: 10.3969/j.issn.1001-5256.2022.08.005
    [3]Wenshang CHEN, Jijin ZHU, Shilai LI. Role of thymic stromal lymphopoietin in liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1175-1178. doi: 10.3969/j.issn.1001-5256.2022.05.042
    [4]Rui SONG, Jing LI, Hongju YANG, Minyue LI, Jing YOU. Role of signal transducer and activator of transcription 1 in regulation of Treg/Th17 balance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2627-2631. doi: 10.3969/j.issn.1001-5256.2022.11.038
    [5]Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association, Chinese Society of Perinatal Medicine, Chinese Medical Association. 2020 clinical guidelines on prevention of mother-to-child transmission of hepatitis B virus[J]. Journal of Clinical Hepatology, 2020, 36(7): 1474-1481. doi: 10.3760/cma.j.cn112141-20200213-00101
    [6]Li Yao, Wang ZhiXin, Wen Hao, Wang HaiJiu, Cai RangDongZhi, Yu WenHao, Zhang Li, Fan HaiNing. Endoplasmic reticulum stress signaling pathway and its association with liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(2): 464-467. doi: 10.3969/j.issn.1001-5256.2020.02.051
    [7]Liu Jia, Zhu QinMei, Hu HongYi, Wang Su. Research advances in Hedgehog signaling pathway in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(2): 300-304. doi: 10.3969/j.issn.1001-5256.2015.02.041
    [8]Zhou XueLing, Yu ShuiPing. Role of Wnt signaling pathway in progression of liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(9): 1540-1542. doi: 10.3969/j.issn.1001-5256.2015.09.045
    [9]Pan Jin, Ju Jian. Current perspectives on the JAK/STAT signaling pathway and its activating factors in liver fibrosis[J]. Journal of Clinical Hepatology, 2013, 29(5): 393-396.
    [11]Hou YuanPei, Liu ChengYong, Gao YuJin. Affection of the mutations and genotypes of hepatitis B virus precore and basic core promoter on HBeAg expression[J]. Journal of Clinical Hepatology, 2007, 23(4): 251-253.
    [12]Xie Fang, Lin ZunHui, Jin HaiYing, Guo XiangHua, Huang YanXiang, Yin JiMing, Yan Yan, Hao Wa, Niu JingQin, Li Zhuo. The applied value of Dane granule antigen of hepatitis B viral in detecting chronic hepatitis B infection[J]. Journal of Clinical Hepatology, 2007, 23(6): 415-417.
    [13]Liu ChengYong, Hou YuanPei, Qian XiuMei, Sun Qing, Song Li. Distribution of hepatitis B virus genotype in Xuzhou and its clinical significance[J]. Journal of Clinical Hepatology, 2005, 21(3): 151-152.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(6)

    1. 胡怡，武思仙，刘栋，张宇. 中医药调控JAK-STAT通路治疗银屑病的研究进展. 中成药. 2024(02): 531-536 .
    2. 唐小标，唐芳，唐满华，盘箐，罗四维，唐萍. 白细胞介素11对急性肝衰竭大鼠肝细胞凋亡及JAK/STAT信号通路的影响. 中国病原生物学杂志. 2024(03): 302-307 .
    3. 王松，熊壮，姜雨辛，刘铁军. 中医药防治肝癌复发转移作用机制的实验研究进展. 吉林中医药. 2023(04): 484-488 .
    4. 李扬，徐骏驰，陈帆，顾赛红，朱传武，李明. 细胞因子信号转导抑制因子3在慢加急性肝衰竭小鼠的表达. 江苏医药. 2023(04): 325-329+320 .
    5. 孙文雄，李蒲. SOCS3在弥漫大B细胞淋巴瘤患者外周血单个核细胞中的表达及其对OCI-LY7细胞自噬和凋亡的影响. 吉林大学学报(医学版). 2022(01): 172-179 .
    6. 李敏玥，杨红菊，李静，宋瑞，游晶. 慢性乙型肝炎信号转导及转录激活因子3、5与Treg/Th17平衡的关系. 临床肝胆病杂志. 2022(06): 1393-1397 . 本站查看

    Other cited types(3)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (915) PDF downloads(68) Cited by(9)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1659]YesterdayPV[2864]TodayIP[211]TodayPV[357]Online[18]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return